Cancer and Translational Medicine Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, Finland.
Department of Molecular medicine and Surgery, Upper Gastrointestinal Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Am J Surg Pathol. 2019 Feb;43(2):229-234. doi: 10.1097/PAS.0000000000001181.
Tumor budding has been associated with poor prognosis in several cancer types, but its significance in gastric cancer is unknown. The aim of this study was to assess the prognostic significance of tumor budding in gastric adenocarcinoma, and its main histologic types. Some 583 gastric adenocarcinoma patients who underwent surgery in Oulu University Hospital during the years 1983-2016 were included in this retrospective cohort study. Tumor budding was counted per 0.785 mm fields from the slides originally used for diagnostic purposes. Patients were divided into low-budding (<10 buds) and high-budding (≥10 buds) groups. Tumor budding was analyzed in relation to 5-year survival and overall survival. Cox regression was used to calculate hazard ratios (HR) with 95% confidence intervals (CI), adjusted for confounders. Determining tumor budding was difficult in diffuse-type cancer due to the uncohesive growth pattern of these tumors. Patients with high tumor budding had worse 5-year survival compared with patients with low tumor budding (adjusted HR, 1.55; 95% CI, 1.20-2.01). In intestinal-type adenocarcinomas, the high-budding group had significantly poorer 5-year survival compared with the low-budding group (adjusted HR, 1.57; 95% CI, 1.14-2.15). There were no differences in 5-year survival between the budding groups in the diffuse type adenocarcinoma. In conclusion, high tumor budding is an independent prognostic factor in gastric adenocarcinoma, but its value is limited to the intestinal type of gastric adenocarcinoma. In diffuse type gastric adenocarcinoma, the assessment of tumor budding is hardly feasible, and it does not have prognostic relevance.
肿瘤芽殖与多种癌症类型的不良预后相关,但在胃癌中的意义尚不清楚。本研究旨在评估胃腺癌及其主要组织学类型中肿瘤芽殖的预后意义。本回顾性队列研究纳入了 1983 年至 2016 年期间在奥卢大学医院接受手术治疗的 583 例胃腺癌患者。从最初用于诊断目的的切片中每 0.785mm ² 计算肿瘤芽殖数。患者被分为低芽殖(<10 个芽)和高芽殖(≥10 个芽)组。分析肿瘤芽殖与 5 年生存率和总生存率的关系。使用 Cox 回归计算风险比(HR)及其 95%置信区间(CI),并进行混杂因素调整。由于这些肿瘤的非黏附生长模式,弥漫型癌症中确定肿瘤芽殖较为困难。高芽殖组患者的 5 年生存率较低芽殖组患者差(调整 HR,1.55;95%CI,1.20-2.01)。在肠型腺癌中,高芽殖组患者的 5 年生存率明显低于低芽殖组患者(调整 HR,1.57;95%CI,1.14-2.15)。弥漫型腺癌中两组患者的 5 年生存率无差异。总之,高肿瘤芽殖是胃腺癌的独立预后因素,但仅限于肠型胃腺癌。在弥漫型胃腺癌中,评估肿瘤芽殖几乎不可行,且与预后无关。